Table 4. Genes identified in our microarray and compared with other data.
| Gene Bank |
Accession # |
Late Changes, 35 days |
Ratio 96hrs/0hr |
Description |
|
AA946503 |
NM 130741.1 |
25.9 |
32.1 |
*Lcn2, lipocalin 2 |
| XI3044 |
NM 013069.1 |
19.6 |
2 0 |
*Cd74 antigen |
|
X52477 |
NM 016994.1 |
10 |
31.6 |
*C3, complement component 3 |
|
J02962 |
NM 031832.1 |
7.9 |
3.0 |
*Lgals3, IgE binding prolein |
|
D88250 |
NM 138900.1 |
4.7 |
9.6 |
*C 1 s, complement component I, s subcomponent |
|
M32062 |
NM 053843.2 |
4.3 |
4.8 |
*Fcgr3, Fc receptor, IgG, low affinity III |
|
AF083269 |
NM 019289.2 |
2.5 |
2.0 |
*Arpclb, actin related protein 2/3 complex |
|
X02601 |
NM 133523.1 |
3.5 |
1.9 |
*Mmp3, matrix metalloproteinase 3 |
|
D90404 |
NM 017097.1 |
3.4 |
1.3 |
Ctsc, cathepsin C |
| J05I22 |
NM 012515.1 |
3.3 |
1.8 |
*Bzrp, benzodiazepin receptor |
| M65I49 |
NM 013154.1 |
8.1 |
7.3 |
*Cebpd, CCAAT/enhancer binding, protein (C EBP) delta |
|
AA945867 |
NM 021835.2 |
4 |
1.2 |
c-jun |
|
AF023087 |
NM 012551.1 |
3.8 |
1.4 |
Egrl, early growth response 1 |
|
L23148 |
NM 012797.1 |
3.8 |
1.2 |
Idl, inhibitor of DNA binding 1 |
| AI0I2030 |
NM 012862.1 |
2.6 |
66.4 |
*Mgp, matrix C51a protein |
|
AFO17437 |
NM 019195.2 |
2.7 |
1.4 |
Cd47, integrin-associated protein |
| XI6072 |
NM 012937.1 |
0.7 |
Crybb2, crystallin, beta B2 |
|
|
AA817854 |
NM 012532.1 |
5.9 |
1.5 |
*Cp, ceruloplasmin |
| All 13289 |
NM 012637.1 |
3.1 |
1.5 |
* Protein-tyrosine phosphatase (Ptpnl) |
|
M96601 |
NM 017206.1 |
-2.1 |
0 8 |
Slc6a6, solute carrier family 6, member 6 |
| M3I837 |
NM 012588.1 |
S |
1.0 |
Igfbp3, insulin-like growth factor binding protein 3 |
| L209I3 |
NM 031836.1 |
4.9 |
1.1 |
Vegf, vascular endothelial growth factor form 3 |
| AA892559 | NM 013166.1 | 2 | 1 6 | *Cntf, ciliary neurotropic factor |
List of differentially expressed genes obtained from our microarray compared with other data reported by Ahmed et al. (2004). The genes show similar fold changes between our study and other study are labeled by asterisk [32]. The selected genes were chosen to be 1.5-fold change or more.